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Malaria parasites have evolved to maintain a well-balanced relationship with their human hosts. This 
implies that they can partially escape from protective effector mechanisms of their hosts, but also that 
hosts can develop partial immunity to the parasite. This immunity requires repeated infections, takes 
years to develop and is usually of short duration. However, protective immunity to clinical malaria 
rather than infection may be of long duration. This natural acquired immunity is called premunition 
since a low parasitemia mostly persists in the presence of circulating antibodies to the various stages 
and in the absence of clinical disease. In children who do not have circulating antibodies to the 
parasite, premunition is probably caused by antitoxic immunity. These poor and slowly developing 
immune responses to malaria are partly due to immune evasion strategies of the parasite caused by 
antigenic polymorphism, shedding of parts of parasite proteins, cross-reactive epitopes of antigens of 
different developmental stages, prolonged exposure to endemic malaria and widespread restricted 
immunogenicity to defined antigens. Premunition relies on the cooperation between the parasite and 
human antibodies, leading to the induction of antibody dependent cellular inhibition (ADCI) of the intra-
erythrocytic growth of the parasite. The immunity, however, is not a sterilizing type in that the infection 
persists longer than the symptoms and individuals can exhibit relapses or recrudescences or become 
reinfected. 
 





The most unique characteristic of a parasite when it is in 
its normal host is its ability to make itself tolerated, which 
clearly indicates that it has sophisticated means to 
ensure the neutrality of its host. This is true in the case of 
Plasmodium falciparum, since after numerous malaria 
attacks, equilibrium is reached with a chronic stage of 
infection, characterized by a relatively low parasitemia 
and low or no disease. This natural defense mechanism 
known as premunition relies on the cooperation between 
the parasite and circulating human antibodies to the various 
stages, leading to an antibody dependent cellular inhibi-
tion (ADCI) of the intra-erythrocytic growth of the parasite 
(Pérignon and Druilhe, 1994). In children who do not have 
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could probably be caused by ‘antitoxic immunity’ (Day 
and Marsh, 1991). 
Malaria parasites have evolved to maintain a well-
balanced relationship with their human hosts. This 
implies that they can partially escape from protective 
effector mechanisms of their hosts, but also that hosts 
can develop partial immunity to the parasite. This immu-
nity requires repeated infections, takes years to develop 
and is usually of short duration, although protective 
immunity to clinical malaria rather than infection may be 
of long duration (Deloron and Chougnet, 1992).  
These poor and slowly developing immune responses 
to malaria are partly due to immune evasion strategies of 
the parasite caused by antigenic polymorphism, shedding 
of parts of parasite proteins, cross-reactive epitopes of 
antigens of different developmental stages, prolonged 
exposure to endemic malaria and widespread restricted 
immunogenicity to defined antigens (Mendis et  al., 1991;  




Mercereau-Puijalon et al., 1991; Conway, 1997). Pre-
munition has been described in malaria hyperendemic 
areas of Africa and Papua New Guinea, while its occur-
rence in Asia is said to be doubtful (Soe et al., 2001). 
In view of the high prevalence of malaria, its threat to 
life and search for the development of effective vaccine, it 
is of utmost interest therefore to gather an understanding 
of the underlying mechanisms of premunition and of their 
target antigens, in order that awareness may be created 
as to the existence of this mode of natural protective 
immunity, its elimination by indiscriminate and uncontrolled 
use of antimalaria drugs and its possible strategic role in 




PREMUNITION IN Plasmodium falciparum 
 
In areas with heavy transmission, areas regarded as 
holoendemic or hyperendemic, malaria infection occurs 
throughout the year, with children having high parasitemia 
and spleen rates (> 50%), while adolescents and adults 
generally having low parasitemia rates. The incidence of 
malaria disease is therefore high in younger children who 
are developing immunity and the pregnant especially the 
primigravida. The older population generally has immu-
nity and premunition to malaria (that is, they have asymp-
tomatic parasitemia). Conversely, in areas of seasonal 
and/or low malaria transmission, the population generally 
does not develop solid immunity and premunition to 
malaria. The infection and disease can therefore occur in 
both children and adults and following periods of reduced 
malaria transmission, there could be the danger of 
malaria epidemics developing (Druilhe and Khusmith, 
1987).  
Immune response against malaria parasite could be 
directed at either the pre-erythrocytic or erythrocytic stages 
of the parasite’s life cycle. However, the erythrocytic 
stage of the life cycle is probably the most important in 
terms of clearing the parasite and lessening the disease. 
Due to the lack of HLA molecules on the surface of the 
parasite or the erythrocyte, it is usually assumed that 
antibody will play a key role in blood-stage immunity. 
Possible effector mechanisms for antibody include: 
blocking erythrocyte invasion by merozoites, antibody-
dependent cellular killing mediated by cytophilic antibodies, 
or increased clearance of infected erythrocytes due to 
binding of antibodies to parasite antigens exposed on the 
erythrocyte surface. All these immune activities lead to a 
lower parasitemia (Bahouroun-Tayoun et al., 1990). 
Almost always, a person will exhibit severe symptoms 
on their initial exposure to malaria, while subsequent 
ones will be less severe, providing the appropriate 
environment for immunity against the disease which is 
slow and requires multiple exposures, to develop (Baird 
et al., 1991). 





in periodicity as the host develops immunity. This immu-
nity, however, is not a sterilizing type in that the infection 
persists longer than the symptoms and individuals can 
exhibit relapses or recrudescences or become reinfected. 
If untreated, P. falciparum is capable of producing a 
chronic, severe and lethal infection (Smith et al., 1999; 





By the World Health Organisation (WHO) definition, there 
are 2 types of relapses (that is, renewed parasite and 
clinical activity) which are the most striking features of 
chronic malaria. These are recurrence and recrudescence. 
The later form of relapse is due to the persistence of 
indetectable erythrocytic forms in the blood of the patient 
after a primary attack of malaria leading to the induction 
of humoral immune responses (IgG and IgM) in response 
to parasitic antigens. These responses are effective 
against the asexual blood forms (mature schizonts and 
free merozoites), keeping them at a low subclinical level; 
they are however, not effective against persisting intra-
hepatic forms of parasites. A balance is achieved between 
infection and resistance- the stage of immune infection or 
premunition. This balance can be disturbed by inter-
current illness such as diarrhoea and malnutrition or long 
absence from the endemic area (and therefore lack of 
continuing antigenic stimuli) or splenectomy. As a result, 
after this period of low parasite density, the erythrocytic 
parasites, undergo repeated erythrocytic multiplication 
and become numerous enough to cause a renewed 
clinical paroxysmal attack. This form of relapse occurs 
with the four species of human plasmodia (Da Silva, 
2002; Males et al., 2008).  
 
1. Premunition is not a sterilizing type of immunity: 
chronic infection persists, although the maximum parasite 
load reached is low. Even if it adds a little in terms of 
reduction of parasite load as compared to innate resis-
tance, this additional immunity is substantial in terms of 
morbidity as it keeps the parasite load low, below the 
threshold of pathogenicity. Superinfection can occur, but 
it remains at a low grade. 
2. It is seen in holo and hyperendemic areas, mainly in 
Africa (and in some regions in Papua New Guinea). 
3. It is independent of transmission levels provided it 
occurs at least once a year. 
4. It is rapidly lost: exactly one year without re-challenge 
is enough to lose this protective state. 
5. It is strain independent. 
6. It is clearly immunoglobulin G (IgG) dependent. 
7. The delay of acquisition is remarkably long, compared 
to the rate of transmission. Epidemiological studies in the 
above areas have helped to define three clinical periods: 
a short period of 0 - 5 years where mortality can occur; a 





(though decreasing in frequency with age); thereafter a 
longer period of premunition where the disease in any 
form is absent. However such epidemiological studies do 
not allow distinguishing the respective importance of the 
immunological competence of the subjects related to age 
and of the long term exposure of the parasite. 
8. It is the strongest type of immunity developed by 
humans against the asexual blood stage (ABS) infection 





The poor and slowly developing immune responses to 
malaria are partly due to immune evasion strategies of 
the parasite. Among these strategies, antigenic polymor-
phism could be considered the most important requiring 
that after infection an individual will acquire immunity only 
to that specific isolate, but not to heterologous parasites 
(Mendis et al., 1991; Mercereau-Puijalon et al., 1991; 
Conway, 1997). Among the many polymorphic antigens 
of P. falciparum the polymorphism in the erythrocyte 
membrane proteins of the EMP-1 family is very extensive 
and serves immune evasion tremendously. These EMPs 
are found in the knob structures which are involved in 
attachment of infected erythrocytes to vascular endothelium 
allowing the parasite to avoid splenic death (Baruch et 
al., 1996). The EMP-1 proteins are encoded by a com-
prehensive set of genes, known as var (for variation) 
genes, of which already 150 different genes scattered 
over the entire P. falciparum genome are known (Borst et 
al., 1995; Baruch et al., 1995; Su et al., 1995; Smith et 
al., 1995).  
In each infected red blood cell only one or at most a 
few var genes are expressed and the rate of switching 
between the genes may be as high as 2.4% per 
generation (Smith et al., 1995). This enables the parasite 
to evade immune attack. Similarly, many other antigens 
may have a high antigenic diversity which may be the 
product of multiple copies of genes (Miller et al., 1996). In 
addition, shedding of parts of parasite proteins may have 
immune evasion purposes as well. Consequently, the 
310 kDa large sexual stage proteins Pfs230 could origin-
nate from a 360 kDa precursor (Williamson et al., 1995, 
1996) while the 50 kDa protein that is shed contains very 
immunogenic amino acid repeats (Riley et al., 1995). The 
immune response, as a result is diverted to this irrelevant 
epitope by a deceptive effect, thereby suppressing the 
formation of high-affinity anti-Pfs230 antibodies. It is 
thought that the many cross-reactive epitopes of antigens 
of different developmental stages are also a heritage of 
the parasite’s ability to divert the immune system (Moelans 
et al., 1992). Very often these cross-reactive epitopes 
confer immunodominant amino acid repeats, with the 
implication that the formation of antibodies to important 
adjacent areas is suppressed (Moelans et al., 1992).  
There   is  also  evidence  that  prolonged  exposure  to  




endemic malaria lowers the immune responsiveness of 
populations to malarial antigens (Riley et al., 1989; 
Goonewardene et al., 1990; Mshaba et al., 1990). This 
down-regulation, accompanied with an increased fre-
quency of CD8+ cells, elevated levels of free CD8 and a 
decreased frequency of CD4+ T cells, may also be the 
result of a (cytokine-mediated) defective activation of 
helper T cells, activation of suppressor T cells and of lym-
phocyte reallocation, but the underlying mechanisms are 
not understood (Hviid et al., 1992). Finally, a widespread 
restricted immunogenicity to defined antigens is being 
reported (Quakyi et al., 1989). To this non-malaria 
disease, immunity and vaccine development responsive-
ness may be partially due to genetic factors. The impli-
cation is that malaria vaccine strategies limited to one 
single antigen subunit approach will be inadequate. 
There is a clear cut evidence of the role of protective 
antibodies in the induction of premunition in vivo. The 
efficacy of these antibodies is however dependent on 
their cooperation with effector cells like monocytes, 
macrophages and the polymorphonuclear (PNM) phago-
cytes. These phagocytes readily opsonize merozoites in 
vivo (Lunel and Druilhe, 1989). However in a study to 
determine the cooperation of various cell types with 
protective antibodies and their effect on parasite survival 
within the erythrocyte, only monocytes were found to 
interact with ADCI to inhibit the growth of P. falciparum 
within the erythrocyte.  
In a study to determine the in vitro mechanism of 
premunition, Bahouroun-Tayoun et al. (1990) used 
biological materials derived from IgG passive transfer 
experiment, to further support the relevance of ADCI in 
protective immunity against malaria. They observed that 
IgG enhanced the growth of P. falciparum and that 
monocytes on their part did not inhibit the parasite. How-
ever, when these immune cells were allowed to act 
together, a very strong inhibition rate was reportedly 
observed prompting the workers to conclude that their 
study was the first direct demonstration of in vitro inhibi-
tory effect of antibodies with proven in vivo protective 
efficacy. In the activities of ADCI to bring about 
premonition, 
 
a) Monocytes are triggered by cytophilic antibodies 
directed against a merozoite surface antigen. 
b) This is followed by the release of tumor necrosis factor 
(TNF), interferons (IFN) and other soluble inflammatory 
mediators. 
c) These soluble mediators then block the division of 
intra-erythrocytic parasites at the trophozoite stage 
(Pérignon and Druilhe, 1994).  
 
Several other workers (Sabchaeron et al., 1991; Soe et 
al., 2001; Vardo et al., 2007) have also investigated the 
activities of ADCI in detail and have reported that the 
delay in immunoglobulin inoculation and the beginning of 
the decrease of parasitemia is not the same in all patients.  




They further posited that the rupture of mature schizonts 
was required to trigger the mechanism mediated by 
antibodies in vivo without being able to distinguish between 
schizonts and merozoites. The report concluded that there 
was a correlation in vivo between the parasite reduction 
rate induced by IgG and the initial level of parasitemia, 
further supporting earlier findings that parasites are involved 
in the triggering of ADCI. 
ADCI as a defense mechanism triggered by merozoites 
and acting on intra-erythrocytic parasites also provides 
an understanding of the chronicity of malaria. According 
to this finding the intra-erythrocytic parasite matures, 
possibly for several cycles, until the number of released 
merozoites reaches the threshold sufficient to trigger 
some monocytes. The parasite being both the trigger and 
the target of ADCI, parasitemia will never go to zero but 
will rather fluctuate at very low levels (Druilhe and 
Khusmith, 1987).  
ADCI has also been found to be associated with one 
important feature of premunition, that is, absence of 
strain specificity. Their activities are extended to even 
mutants devoid of specific targets to protective anti-
bodies, provided monocytes are triggered by “wild type” 
parasites (Bahouroun-Tayoun and Druilhe, 1992). 
 
 
AGE DEPENDENT ACQUIRED PROTECTION  
 
Susceptibility and death rates in P. falciparum malaria are 
high during childhood. Parasitemia and recurrent episodes 
of clinical malaria are also common among this age 
group. Gradually the children begin to have intermittent 
absence of parasitemias, followed by lower density 
parasitemias, splenomegaly and finally premunition. 
Adolescents and adults on the other hand sometimes 
have parasitemia and occasionally clinical symptoms of 
malaria. Conversely, pregnant women especially primi-
gravida (first pregnancy) are highly susceptible to malaria 
infections and serious disease since their natural defense 
mechanisms are reduced during pregnancy. Besides, 
immunological influences, malaria infection could also be 
controlled by antimalarial treatments. Inadequate anti-
malarial treatments may prolong the presence of malaria 
parasites in the host and this may serve as a prerequisite 
for the acquisition of protective immunity against re-
infection (White, 1998; Ai Long et al., 2002). However, 
use of anti-malaria drugs has been reported to delay the 
process of developing malaria immunity, with people who 
use one form of malaria prophylaxis or another being 
liable to develop severe clinical disease on re-exposure 
(Baird et al., 1991).  
Acquired antibody-mediated immunity has also been 
reported to be transferred from mother to feotus across 
the placenta. This passively transferred immunity is lost 
within 6 to 9 months, as is the immunity in adults if they 
leave a malarious area and are no longer exposed to 







In humans repeated infection by P falciparum induce a 
progressive modulation of the immune response, 
eventually leading to an anti-parasite immunity charac-
teristic of premunition. This progressive modulation of the 
immune response, clearly exemplified by the acquisition 
of in vivo protective antibodies able to promote in vitro, an 
ADCI effect, is important to consider, as it implied that 
antimalarial immunity should be assessed not only on 
quantitative terms (the higher the titer the best), but also 
from a qualitative point of view (the right antibody co-
operating with the right cell). Besides immunological 
influences, malaria infection could also be controlled by 
antimalarial treatments; but inadequate antimalarial treat-
ments may prolong the presence of malaria parasites in 
the host and this may serve as a prerequisite for the 
acquisition of protective immunity against re-infection. 
However, use of anti-malaria drugs has been reported to 
delay the process of developing malaria immunity, with 
people who use one form of malaria prophylaxis or 
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